Holen Sie sich die Stockscreener-App
7.08
1.12%
-0.08
Schlusskurs vom Vortag:
$7.16
Offen:
$7.16
24-Stunden-Volumen:
118.05K
Relative Volume:
1.62
Marktkapitalisierung:
$407.05M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
26.22
EPS:
0.27
Netto-Cashflow:
$10.92M
1W Leistung:
-1.80%
1M Leistung:
+20.00%
6M Leistung:
+22.49%
1J Leistung:
+20.61%
1-Tages-Spanne:
$6.90
$7.1624
1-Wochen-Bereich:
$6.90
$7.35
52-Wochen-Spanne:
$4.74
$8.00
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.08 | 407.05M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-03 | Eingeleitet | Stifel | Buy |
| 2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December - MarketBeat
Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright - Defense World
Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% Higher - Simply Wall St
Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations - Yahoo Finance
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 - GlobeNewswire
Kamada Projects Strong 2025 Growth: 13% Revenue Jump to $182M, EBITDA to Rise 19% - StockTitan
KMDA stock touches 52-week high at $6.53 amid market optimism By Investing.com - Investing.com South Africa
Kamada (NASDAQ:KMDA) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Comparing Endonovo Therapeutics (OTCMKTS:ENDVD) & Kamada (NASDAQ:KMDA) - Defense World
KMDA stock touches 52-week high at $6.53 amid market optimism - Investing.com Australia
Financial Survey: Kamada (NASDAQ:KMDA) versus Endonovo Therapeutics (OTCMKTS:ENDVD) - Defense World
Exploring High Growth Tech Stocks This January 2025 - Yahoo Finance
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Exploring Undiscovered Gems with Potential This December 2024 - Simply Wall St
So who replaces Eberechi Eze against Arsenal? Crystal Palace boss asked if summer signing will step in - South London News
Music Industry Moves: Avex USA Names Ryusuke Kamada CFO - Yahoo Entertainment
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment - TipRanks
Gauzy Appoints Lilach Payorski to Board - Glass Magazine
Gauzy Adds to Board of Directors - CleanLink
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay Packet - Simply Wall St
Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 8.9% - Defense World
Gauzy Appoints Seasoned Public Company Executive and Director Lilach Payorski to Board of Directors - The Manila Times
Gauzy Strengthens Board with Ex-Stratasys CFO Lilach Payorski as Audit Chair | GAUZ Stock News - StockTitan
Maxkamada Banaadir oo soo saartay Waaran lagu soo xirayo Madaxweynaha Jubaland - Horseed Media
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business - Simply Wall St
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
HC Wainwright Issues Pessimistic Outlook for Kamada Earnings - MarketBeat
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com India
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook By Investing.com - Investing.com Australia
Kamada: Q3 Earnings Snapshot - Barchart
Kamada reports Q3 EPS 7c, consensus 7c - TipRanks
Kamada’s Strong Growth and Strategic Expansion in 2024 - TipRanks
KMDAKamada Ltd Latest Stock News & Market Updates - StockTitan
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance - The Manila Times
Kamada Reports Continued Profitable Growth with Strong - GlobeNewswire
Kamada Q3 Revenue Surges 10% to $41.7M, Boosts EBITDA Guidance Amid Strong Growth | KMDA Stock News - StockTitan
How Oliver Glasner can get the best out of Daichi Kamada after terrible start - We Are Palace
Report shares who was actually responsible for bringing Daichi Kamada to Crystal Palace - We Are Palace
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):